{"doi":"10.1002/cmdc.201200319","title":"Modeling, Synthesis and Biological Evaluation of Potential Retinoid X Receptor‐Selective Agonists: Novel Halogenated Analogues of 4‐[1‐(3,5,5,8,8‐Pentamethyl‐5,6,7,8‐tetrahydro‐2‐naphthyl)ethynyl]benzoic Acid (Bexarotene)","abstract":"<jats:title>Abstract</jats:title><jats:p>The synthesis of halogenated analogues of 4‐[1‐(3,5,5,8,8‐pentamethyl‐5,6,7,8‐tetrahydro‐2‐naphthyl)ethynyl]benzoic acid (<jats:bold>1</jats:bold>), known commonly as bexarotene, and their evaluation for retinoid X receptor (RXR)‐specific agonist performance is described. Compound <jats:bold>1</jats:bold> is FDA approved to treat cutaneous T‐cell lymphoma (CTCL); however, bexarotene treatment can induce hypothyroidism and elevated triglyceride levels, presumably by disrupting RXR heterodimer pathways for other nuclear receptors. The novel halogenated analogues in this study were modeled and assessed for their ability to bind to RXR and stimulate RXR homodimerization in an RXRE‐mediated transcriptional assay as well as an RXR mammalian‐2‐hybrid assay. In an array of eight novel compounds, four analogues were discovered to promote RXR‐mediated transcription with EC<jats:sub>50</jats:sub> values similar to that of <jats:bold>1</jats:bold> and are selective RXR agonists. Our approach also uncovered a periodic trend of increased binding and homodimerization of RXR when substituting a halogen atom for a proton <jats:italic>ortho</jats:italic> to the carboxylic acid on <jats:bold>1</jats:bold>.</jats:p>","journal":"ChemMedChem","year":2012,"id":664480,"datarank":0.6466142845882884,"base_score":3.2188758248682006,"endowment":3.2188758248682006,"self_citation_contribution":0.48283137373023016,"citation_network_contribution":0.16378291085805827,"self_endowment_contribution":0.48283137373023016,"citer_contribution":0.16378291085805827,"corpus_percentile":null,"corpus_rank":null,"citation_count":24,"citer_count":12,"citers_with_citation_signal":9,"citers_with_endowment":9,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1735028,"name":"Ichiro Kaneko","orcid":null,"position":1,"is_corresponding":false},{"id":1735030,"name":"Angela N. Walsh","orcid":null,"position":2,"is_corresponding":false},{"id":1449976,"name":"Joanna Yang","orcid":"0000-0003-0455-0635","position":3,"is_corresponding":false},{"id":1735034,"name":"Jaskaran S. Bhogal","orcid":null,"position":4,"is_corresponding":false},{"id":1735035,"name":"Geoffrey M. Gray","orcid":null,"position":5,"is_corresponding":false},{"id":1735036,"name":"Juan C. Baso","orcid":null,"position":6,"is_corresponding":false},{"id":1735037,"name":"Drew O. Browder","orcid":null,"position":7,"is_corresponding":false},{"id":1735038,"name":"Jessica L. S. Prentice","orcid":null,"position":8,"is_corresponding":false},{"id":1735039,"name":"Luis A. Montano","orcid":null,"position":9,"is_corresponding":false},{"id":1735040,"name":"Chanh C. Huynh","orcid":null,"position":10,"is_corresponding":false},{"id":1735041,"name":"Lisa M. Marcus","orcid":null,"position":11,"is_corresponding":false},{"id":1735042,"name":"Dorian G. Tsosie","orcid":null,"position":12,"is_corresponding":false},{"id":1735043,"name":"Jungeun S. Kwon","orcid":null,"position":13,"is_corresponding":false},{"id":1490077,"name":"Alexis Quezada","orcid":null,"position":14,"is_corresponding":false},{"id":1735044,"name":"Nicole M. Reyes","orcid":null,"position":15,"is_corresponding":false},{"id":1735045,"name":"Brittney Lemming","orcid":null,"position":16,"is_corresponding":false},{"id":1735046,"name":"Puneet Saini","orcid":null,"position":17,"is_corresponding":false},{"id":1735047,"name":"Arjan van der Vaart","orcid":null,"position":18,"is_corresponding":false},{"id":1298760,"name":"Thomas L. Groy","orcid":"0000-0002-0313-1116","position":19,"is_corresponding":false},{"id":14607,"name":"Pamela A. Marshall","orcid":"0000-0002-3530-4368","position":20,"is_corresponding":false},{"id":112733,"name":"Peter W. Jurutka","orcid":null,"position":21,"is_corresponding":false},{"id":112732,"name":"Carl E. Wagner","orcid":null,"position":22,"is_corresponding":false},{"id":1735026,"name":"Julie K. Furmick","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Modeling, Synthesis and Biological Evaluation of Potential Retinoid X Receptor‐Selective Agonists: Novel Halogenated Analogues of 4‐[1‐(3,5,5,8,8‐Pentamethyl‐5,6,7,8‐tetrahydro‐2‐naphthyl)ethynyl]benzoic Acid (Bexarotene)","abstract":"<jats:title>Abstract</jats:title><jats:p>The synthesis of halogenated analogues of 4‐[1‐(3,5,5,8,8‐pentamethyl‐5,6,7,8‐tetrahydro‐2‐naphthyl)ethynyl]benzoic acid (<jats:bold>1</jats:bold>), known commonly as bexarotene, and their evaluation for retinoid X receptor (RXR)‐specific agonist performance is described. Compound <jats:bold>1</jats:bold> is FDA approved to treat cutaneous T‐cell lymphoma (CTCL); however, bexarotene treatment can induce hypothyroidism and elevated triglyceride levels, presumably by disrupting RXR heterodimer pathways for other nuclear receptors. The novel halogenated analogues in this study were modeled and assessed for their ability to bind to RXR and stimulate RXR homodimerization in an RXRE‐mediated transcriptional assay as well as an RXR mammalian‐2‐hybrid assay. In an array of eight novel compounds, four analogues were discovered to promote RXR‐mediated transcription with EC<jats:sub>50</jats:sub> values similar to that of <jats:bold>1</jats:bold> and are selective RXR agonists. Our approach also uncovered a periodic trend of increased binding and homodimerization of RXR when substituting a halogen atom for a proton <jats:italic>ortho</jats:italic> to the carboxylic acid on <jats:bold>1</jats:bold>.</jats:p>","is_dataset_classified":null,"base_score":3.2188758248682006,"endowment":3.2188758248682006,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"22927238","pmcid":"PMC3479356","openalex_id":"https://openalex.org/W2171026805","authors":[],"funders":[{"funder_name":"NCI NIH HHS","grant_id":"R15 CA139364","title":null},{"funder_name":"NCI NIH HHS","grant_id":"1 R15 CA139364-01A2","title":null}],"total_grants":2,"fwci":0.8595,"citation_percentile":0.72257626,"influential_citations":0,"citation_trend":[{"year":2012,"count":1},{"year":2013,"count":4},{"year":2015,"count":2},{"year":2016,"count":3},{"year":2017,"count":2},{"year":2018,"count":2},{"year":2019,"count":2},{"year":2020,"count":2},{"year":2021,"count":2},{"year":2022,"count":2},{"year":2023,"count":1},{"year":2025,"count":1}],"oa_status":"closed","license":"http://onlinelibrary.wiley.com/termsAndConditions#vor","oa_locations":[{"url":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcmdc.201200319","host_type":"publisher"},{"url":"https://chemistry-europe.onlinelibrary.wiley.com/doi/pdf/10.1002/cmdc.201200319","host_type":"publisher"},{"url":"https://doi.org/10.1002/cmdc.201200319","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/22927238","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3479356","host_type":"repository"}],"fields_of_study":["Retinoids in leukemia and cellular processes","Estrogen and related hormone effects","Antioxidant Activity and Oxidative Stress","Animals","Anticarcinogenic Agents","Apoptosis","Bexarotene","Cell Line, Tumor","Halogenation","Humans","Lymphoma, T-Cell, Cutaneous","Molecular Docking Simulation","Neoplasms","Protein Multimerization","Retinoid X Receptors","Tetrahydronaphthalenes"],"mesh_terms":["Bexarotene","Animals","Humans","Neoplasms","Tetrahydronaphthalenes","Lymphoma, T-Cell, Cutaneous","Anticarcinogenic Agents","Apoptosis","Cell Line, Tumor","Retinoid X Receptors","Halogenation","Protein Multimerization","Molecular Docking Simulation"],"keywords":["Bexarotene","Retinoid X receptor","Agonist","Nuclear receptor","Chemistry","Retinoid","Receptor","Retinoid X receptor alpha","Stereochemistry","Retinoid X receptor beta","Biochemistry","Pharmacology","Transcription factor","Biology","Retinoic acid","Gene"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"gen"},{"name":"pdb"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-13T03:04:21.868783Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}